EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer

Angela Abdollahi, Margaret Favata, Michael Weber, Valerie Roman, Rodrigo Hess, Kayla Hammond, Matthew R Farren iD, Mike Schaffer, Aidan Gilmartin, Hui Wang, Jonathan Rios-Doria iD, Alejandro Amador-Arjona

PLOS One · 11.08.2025 · 20 (8) · e0327588

DOI: 10.1371/journal.pone.0327588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 11.08.2025. Verfasst von Angela Abdollahi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Incyte Research Institute, Wilmington, Delaware, United States of America. Hauptthemen laut MEDLINE: Lung Neoplasms, Drug Resistance, Neoplasm, Proto-Oncogene Proteins p21(ras), Pyrimidines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Incyte.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS mutations are high prevalence oncogenic drivers for multiple cancers. With the advent of new classes of KRAS inhibitors that are showing meaningful clinical activity, research is now turning to questions of optimal combinations of therapies for specific indications, as many patients with KRAS G12C mutations do not respond and/or develop resistance to single-agent treatment. Here, we investigate combination therapies that may overcome resistance to KRAS G12C inhibitors. We found that pemigatinib, a potent and selective FGFR1–3 inhibitor, had a significantly high Bliss synergy score in combination with KRAS G12C inhibitors, and FGFR1 activity was shown to decrease KRAS G12C-dependency conferring inherent resistance in mesenchymal-like cell lines. Knockdown experiments verified the importance of FGFR1, but not FGFR2-4, for the synergistic effect with KRAS G12C inhibitors. Additionally, human lung cancer xenograft and patient-derived xenograft models with a mesenchymal phenotype and high FGFR1 expression were sensitive to the combination of G12C inhibitors and pemigatinib. In short, we demonstrate that pemigatinib and KRAS G12C inhibitors are promising agents for combination therapy in non-small cell lung cancer with a mesenchymal-like phenotype harboring high FGFR1 expression and KRAS G12C mutations to broaden patient response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsDrug Resistance, NeoplasmProto-Oncogene Proteins p21(ras)PyrimidinesReceptor, Fibroblast Growth Factor, Type 1PyridazinesProtein Kinase InhibitorsHumansAnimalsCell Line, TumorMiceXenograft Model Antitumor AssaysMorpholinesMutationDrug SynergismPyrroles

Substanzen

Proto-Oncogene Proteins p21(ras)PyrimidinesReceptor, Fibroblast Growth Factor, Type 1pemigatinibPyridazinesKRAS protein, humanFGFR1 protein, humanMorpholinesProtein Kinase InhibitorsPyrroles

Autor:innen und Institutionen

  • Incyte Research Institute, Wilmington, Delaware, United States of America.

ORCID-Profile: Matthew R Farren, Jonathan Rios-Doria

Förderung

  • Incyte

Zitieren

APA

Abdollahi, A., Favata, M., Weber, M., Roman, V., Hess, R., Hammond, K., Farren, M. R., Schaffer, M., Gilmartin, A., Wang, H., Rios-Doria, J., & Amador-Arjona, A. (2025). The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer. PLOS One, 20(8), e0327588. https://doi.org/10.1371/journal.pone.0327588

Vancouver

Abdollahi A, Favata M, Weber M, Roman V, Hess R, Hammond K, et al. The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer. PLOS One. 2025;20(8):e0327588. doi:10.1371/journal.pone.0327588

BibTeX
@article{Abdollahi2025,
  author = {Abdollahi, Angela and Favata, Margaret and Weber, Michael and Roman, Valerie and Hess, Rodrigo and Hammond, Kayla and Farren, Matthew R and Schaffer, Mike and Gilmartin, Aidan and Wang, Hui and Rios-Doria, Jonathan and Amador-Arjona, Alejandro},
  title = {The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {8},
  pages = {e0327588},
  doi = {10.1371/journal.pone.0327588}
}
Kostenlos starten →